Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 70500
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Mapk1
Name: mitogen activated protein kinase 1
Acc ID: CHEBI:49668
Term: gefitinib
Definition: A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer.
Chemical ID: MESH:C419708
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Mapk1multiple interactionsEXP 6480464CTDgefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]PMID:15660382
Mapk1decreases expressionISOMAPK1 (Homo sapiens)6480464CTDgefitinib results in decreased expression of MAPK1 protein modified formPMID:19288272
Mapk1decreases phosphorylationISOMAPK1 (Homo sapiens)6480464CTDGefitinib results in decreased phosphorylation of MAPK1 proteinPMID:17145836 PMID:28942004 PMID:29383186 PMID:35317323 PMID:36807944 PMID:38521369
Mapk1increases phosphorylationISOMAPK1 (Homo sapiens)6480464CTDgefitinib results in increased phosphorylation of MAPK1 proteinPMID:19380191
Mapk1multiple interactionsISOMAPK1 (Homo sapiens)6480464CTDGefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK1 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]PMID:16322342 PMID:17805209 PMID:17898861 PMID:18927496 PMID:19233551 PMID:19318490 PMID:20088784 PMID:21258428 PMID:21544845 PMID:21787763 PMID:24568969 PMID:27087131 PMID:28942004 PMID:29383186 PMID:30993382 PMID:36190352 PMID:38521369
Mapk1multiple interactionsISOMapk1 (Mus musculus)6480464CTDGefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]]PMID:38521369
Go Back to source page   Continue to Ontology report